Muller, Audrey http://orcid.org/0009-0008-9438-539X
Escribano-Subias, Pilar
Fernandes, Catarina C.
Fontana, Martina
Lange, Tobias J.
Söderberg, Stefan
Gaine, Sean
Funding for this research was provided by:
Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson
Article History
Received: 2 October 2023
Accepted: 2 November 2023
First Online: 13 January 2024
Declarations
:
: Audrey Muller is an employee of Janssen Pharmaceutical Companies of Johnson & Johnson and has Johnson & Johnson shares. Pilar Escribano-Subias has received payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing or educational events from Janssen Pharmaceutical Companies of Johnson & Johnson, MSD, Ferrer and AOT, has received support from Janssen Pharmaceutical Companies of Johnson & Johnson and MSD for attending meetings and/or travel and has participated on a Data Safety Monitoring Board or Advisory Board for Janssen Pharmaceutical Companies of Johnson & Johnson, MSD, Ferrer, Gossamer and AOT. Catarina C Fernandes is an employee of Janssen Pharmaceutical Companies of Johnson & Johnson. Martina Fontana is an employee of Janssen Pharmaceutical Companies of Johnson & Johnson. Tobias J Lange has received speaker fees and/or consultancy fees and/or financial and non-financial support for participation in scientific events from Acceleron Pharma, AstraZeneca, Bayer, Böhringer Ingelheim, Ferrer, Gossamer Bio, Janssen Pharmaceutical Companies of Johnson & Johnson, MSD, Orphacare and Pfizer. Stefan Söderberg has received speaker and consultancy fees, and financial support for participation in scientific events from Janssen Pharmaceutical Companies of Johnson & Johnson. Sean Gaine has had relations, such as funding, with the following subjects that have commercial interests in the pharmaceutical and medical field: Aerovate Therapeutics, Acceleron, Altavant, Bayer, Gossamer Bio, Janssen Pharmaceutical Companies of Johnson & Johnson, MSD and United Therapeutics.
: The study was conducted in accordance with the Declaration of Helsinki, the International Society for Pharmacoepidemiology (ISPE) Guidelines for Good Pharmacoepidemiology Practices (GPP) and in accordance with the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) Guide on Methodological Standards in Pharmacoepidemiology. The protocol was approved by the Institutional Review Board or Independent Ethics Committee at each study site (and at the national level in Sweden). Written informed consent was obtained from each patient for accessing and processing anonymised patient data and their use in scientific research.